Novo Nordisk A/S (NYSE:NVO) Position Decreased by Colonial Trust Co SC

Colonial Trust Co SC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 25.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,200 shares of the company’s stock after selling 770 shares during the quarter. Colonial Trust Co SC’s holdings in Novo Nordisk A/S were worth $189,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Cornerstone Select Advisors LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $258,000. Centiva Capital LP raised its position in shares of Novo Nordisk A/S by 50.1% during the fourth quarter. Centiva Capital LP now owns 31,367 shares of the company’s stock worth $2,698,000 after purchasing an additional 10,469 shares during the period. Bridgefront Capital LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $341,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $3,017,000. Finally, Cary Street Partners Financial LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $2,413,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 4.1 %

NYSE:NVO opened at $64.78 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market capitalization of $290.72 billion, a P/E ratio of 19.69, a P/E/G ratio of 0.90 and a beta of 0.65. The stock’s 50 day moving average price is $69.65 and its 200 day moving average price is $86.58. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analysts Set New Price Targets

NVO has been the subject of several recent analyst reports. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating for the company. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.